Bioharvest Sciences, Inc. ( (BHST) ) has released its Q4 earnings. Here is a breakdown of the information Bioharvest Sciences, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioHarvest Sciences Inc. is a biotechnology company specializing in Botanical Synthesis technology to produce plant-based molecules for therapeutic solutions and nutraceutical products, operating primarily as a contract development and production organization (CDMO) and a creator of proprietary health products.
In its latest earnings report, BioHarvest Sciences Inc. announced significant financial growth, with fourth-quarter revenues rising by 62% to $7.3 million and full-year revenues almost doubling to $25.2 million. The company also secured a strategic partnership with Tate & Lyle to develop plant-based sweeteners, marking a notable expansion in its CDMO division.
Key financial highlights include a substantial increase in gross margins, which improved by 600 basis points in the fourth quarter and 1,000 basis points for the full year, reflecting enhanced production efficiency and cost management. The company’s VINIA® product line continued to perform strongly, surpassing 50,000 subscribers, while operating expenses were managed effectively, with a decrease in general and administrative costs.
Looking forward, BioHarvest’s management is optimistic about achieving adjusted EBITDA breakeven in the second half of 2025, driven by continued growth in its product lines and strategic partnerships. The company is poised to leverage its Nasdaq uplisting to accelerate its expansion and engage more effectively with investors, aiming to deliver long-term shareholder value through its diversified business model.